Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 65

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 65
---
ance pay in the form of a lump sum payment equal to 12 months of his final annual base salary following termination;

Either (a) subject to Ms. Henrich’s timely election for continued coverage under COBRA, payment by us of her COBRA premiums for up to 12 months following her termination of employment or (b) if Ms. Henrich is not entitled to COBRA continuation coverage or if we determine that we cannot pay his COBRA premiums without potentially incurring financial costs or penalties under applicable law, payment by us to Ms. Henrich of a fully taxable cash payment equal to the applicable COBRA premiums on the first of each month for up to 12 months following her termination of employment;

Lump sum amount equal to 100% of her target annual bonus for the year in which the termination date occurs; and

Full acceleration and immediate exercisability, if applicable, of all outstanding equity awards subject to time-based vesting conditions.

The receipt of any termination-based payments or benefits by Ms. Henrich was subject to her execution and the effectiveness of a release of claims against the Company.

<div align='center'>41</div>

Pursuant to the Henrich Employment Agreement, if any payments or benefits provided to Ms. Henrich in connection with a change in control are subject to excise taxes as a result of the application of Sections 280G and 4999 of the Internal Revenue Code, such payments and benefits will be reduced so that no excise tax is payable, but only if this reduction results in a more favorable after-tax position for her.

Amar Murugan

We entered into an executive employment agreement with Mr. Murugan in April 2020 (the “Murugan Employment Agreement”) in connection with his joining the Company as our Senior Vice President, General Counsel. Mr. Murugan was promoted to Executive Vice President, Chief Legal Officer in March 2023. In November 2024, Mr. Murugan left the Company and in connection with his departure, he was entitled to receive severance payments and benefits consistent with a termination of employment without cause under the Murugan Employment Agreement, as described below. In addition, in connection with his departure, we entered into a consulting agreement (“Murugan Consulting Agreement”) with Mr. Murugan which superseded and replaced the Murugan Employment Agreement and provided for: (i) Mr. Murugan to relinquish to the Company all of Mr. Murugan’s vested